Ligand Pharmaceuticals Incorporated
Price Action
Technical Summary
STAGE 2 UPTRENDLigand Pharmaceuticals Incorporated is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 88), indicating clear outperformance against the broad market. Earnings growth of 70% provides fundamental context to the price action. However, with RSI at 80, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $244.25 | +7.33% | ABOVE |
| 50 SMA | $231.87 | +13.07% | ABOVE |
| 100 SMA | $215.23 | +21.81% | ABOVE |
| 150 SMA | $208.97 | +25.46% | ABOVE |
| 200 SMA | $201.88 | +29.86% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LGND in an uptrend right now?
LGND has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, LGND is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is LGND overbought or oversold?
LGND's RSI (14) is 80. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is LGND outperforming the market?
LGND has a Relative Strength (RS) Rating of 88 out of 99. Yes, LGND is a market leader, outperforming 88% of all stocks over the past 12 months.
Where is LGND in its 52-week range?
LGND is trading at $262.17, which is 95% of its 52-week high ($276.20) and 92% above its 52-week low ($110.00).
How volatile is LGND?
LGND has a Beta of 0.95 and 52-week volatility of 37%. It's less volatile than the S&P 500 - generally more stable.